Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MAIA $1.85 -MC $22 m -has lung cancer drug that could be approved within 2 years ...
Investment Summary
https://d1io3yog0oux5.cloudfront.net/_28c74c59a9eef004c28b99c8bd7977cd/maiabiotech/db/2216/20714/pdf/2023-07-12+MAIA+Biotechnology+-+TwoPager.pdf
ABVC $1.24 - MCap $ 4 m - dirt cheap low floater with Phase 3 drug ready and 2 others in final Phase 2 with data readout expected during next 6 months
OCUP $3.90 FDA Decision in 21 days , low market cap of $82 million - Cash balance $40 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Cash Balance of $40 Million Expected to Fund Operations into 2025
OCUP $3.90 FDA Decision in 21 days , low market cap of $82 million - Cash balance $40 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Cash Balance of $40 Million Expected to Fund Operations into 2025
OCUP $3.90 FDA Decision in 21 days , low market cap of $82 million - Cash balance $40 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Cash Balance of $40 Million Expected to Fund Operations into 2025
OCUP $3.90 FDA Decision in 21 days , low market cap of $82 million - Cash balance $40 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Cash Balance of $40 Million Expected to Fund Operations into 2025
ABVC $1.25 - MC $5 m- Depression Drug to start Phase 3 soon and another 2 Drugs in final Phase 2 trials with data coming between Q4 and Q1 . dirt cheap low floater with huge product pipeline
Presentation
https://abvcpharma.com/wp-content/uploads/2023/08/ABVC-Corporate-Overview-Summer-2023.pdf
OCUP $3.96 PDUFA date on September 28 and another indication with Phase 3 readout in Q4 ...Market Cap only 84 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Q4 2023)
Cash Balance of $40 Million Expected to Fund Operations into 2025
OCUP $3.96 PDUFA date on September 28 and another indication with Phase 3 readout in Q4 ...Market Cap only 84 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Q4 2023)
Cash Balance of $40 Million Expected to Fund Operations into 2025
OCUP $3.96 PDUFA date on September 28 and another indication with Phase 3 readout in Q4 ...Market Cap only 84 million
Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire
Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Q4 2023)
Cash Balance of $40 Million Expected to Fund Operations into 2025
ATHE $3 big patent news who has an potential blockbuster drug in advanced Phase 2 program ..Market cap only 11 million this could be the next SAVA if Phase 2 data expected next year are positive
KPRX 0.58 patent news ..market cap only 4 million and they are about to release important data readout in the coming weeks
(ABVC) Up 14%+, MC $7 m-- attractive depression drug to start Phase 3 soon plus another 2 drugs in final Phase 2 trial with data readout by year end ..dirt cheap low floater with great product pipeline....
(KPRX) $0.53 -MC $7 m trading at cash and about to release Phase 1 data of their potential blockbuster drug
Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses with Full Topline Results Expected in Q4 2023
Pipeline
https://kiorapharma.com/pipeline/
(ABVC) MC $9m -great buying opp again after the big jump to around $6 early this week . company has vey attractive pipeline with drugs in late stage targeting huge markets like major depression and ADHD check out their latest presentation below . this heavily underpriced low floater could explode again on any good news .
Presentation
https://abvcpharma.com/wp-content/uploads/2023/06/ABVC-Corporate-Overview-Summer-2023.pdf
(TCON) 0.32 - MC $9 m - pivotal interim data imminent (sarcoma drug) ...super cheap cancer play who could file NDA by mid next year a potential 10 bagger and more here guys
“We look forward to reporting the interim efficacy assessment from ENVASARC in the third quarter of 2023, which includes a futility analysis that we have already met based on responses seen to date.”
massive insider buying north of 1 dollar
http://openinsider.com/search?q=tcon
latest presentation
https://traconpharma.gcs-web.com/static-files/4125549b-8456-41a4-a93f-f73cf98c2aa2
(TCON) 0.32 - MC $9 m - pivotal interim data imminent (sarcoma drug) ...super cheap cancer play who could file NDA by mid next year a potential 10 bagger and more here guys
“We look forward to reporting the interim efficacy assessment from ENVASARC in the third quarter of 2023, which includes a futility analysis that we have already met based on responses seen to date.”
massive insider buying north of 1 dollar
http://openinsider.com/search?q=tcon
latest presentation
https://traconpharma.gcs-web.com/static-files/4125549b-8456-41a4-a93f-f73cf98c2aa2
TCON 0.34 insider bought massive above 1 dollar see link below and they still holding all their shares ..imminent data readout expected this quarter .. market cap only 9 million .
Formal efficacy interim analysis expected in 3Q after the 46th patient treated with envafolimab (who was enrolled in 2Q) has completed a minimum of 12 weeks of efficacy evaluations, and includes a futility rule that is currently being exceeded based on available data
Insider buying
http://openinsider.com/search?q=tcon
latest presentation
https://traconpharma.gcs-web.com/static-files/4125549b-8456-41a4-a93f-f73cf98c2aa2
TCON 0.32 - pivotal interim data from sarcoma trial imminent (during Q3)
look at the insider buying in last months
http://openinsider.com/search?q=tcon
(TCON) 0.29 - MC $7 m - pivotal interim data imminent (sarcoma drug) ...super cheap cancer play who could file NDA by mid next year
“We look forward to reporting the interim efficacy assessment from ENVASARC in the third quarter of 2023, which includes a futility analysis that we have already met based on responses seen to date.”
(TCON) 0.29 - MC $7 m - pivotal interim data imminent (sarcoma drug) ...super cheap cancer play who could file NDA by mid next year
“We look forward to reporting the interim efficacy assessment from ENVASARC in the third quarter of 2023, which includes a futility analysis that we have already met based on responses seen to date.”
ABVC up 100%+ and sold it
(ABVC) MC $8 m-- Huge depression drug to start Phase 3 soon plus another 2 drugs in final Phase 2 trial with data readout by year end ...
(APLIF) $0.03 -FDA Decision in September for Antibiotic Drug ..market cap only 3 million ...check out their slide presentation below
https://z5w.be6.myftpupload.com/wp-content/uploads/2023/04/Appili-Corporate-Presentation-FINAL.pdf
(NOVN) $0.55 -MC $15 m - FDA Decision in January for molluscum treatment a disease that affects 6 million americans and with NO FDA approved product to date .This could run to $2-3 even before FDA decision
“It is a very exciting time in pediatric dermatology right now. We have 2 pharmaceutical companies essentially in a race to the finish to get the very first FDA-approved treatment for molluscum contagiosum,” said Miranti. “I'm sure that a lot of dermatology advanced practice providers like myself will be extremely excited to get our hands on these products. Because right now there's nothing FDA-approved for molluscum. It's amazing to think about how molluscum affects 6 million Americans and over 70% go untreated because they just think that they’re just bumps, or they think they're cosmetic, or because they're not causing any pain, they're not such a problem. But it is a contagious condition. It's something that because I work in pediatric dermatology and general dermatology, I see it every single day.”
(TCON) $0.29- MC $7 m- pivotal interim data from their sarcoma treatment expected during this quarter .The drug if successful could be approved within 2 years . this is likely one if not the cheapest cancer play out there
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
https://finance.yahoo.com/news/tracon-pharmaceuticals-announces-collection-arbitration-120000420.html
“We look forward to reporting the interim efficacy assessment from ENVASARC in the third quarter of 2023, which includes a futility analysis that we have already met based on responses seen to date.”
(KOD) $7 - 3x Ph 3 data in JULY and the company still trades under cash, risky gem but if the drug is successful then this has huge upside because of its very large market potential
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
presentation
https://ir.kodiak.com/static-files/837c8ad5-44f2-429f-a91e-b0e96463402d
(KOD) $7 - 3x Phase 3 results in JULY and the company still trades under cash, risky gem but if the drug is successful then this has huge upside because of its very large market potential
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
presentation
https://ir.kodiak.com/static-files/837c8ad5-44f2-429f-a91e-b0e96463402d
TCON $0.29 -Cancer drug near BLA filing expected in 1H 2024 - market cap only 8 million this has potential to be a 10 bagger guys ...
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
https://finance.yahoo.com/news/tracon-pharmaceuticals-announces-positive-results-120000399.html
Company Presentation
https://traconpharma.gcs-web.com/static-files/4125549b-8456-41a4-a93f-f73cf98c2aa2
OCUP $4.20 next to breakout with FDA decision is sight (see previous post for more info)
OCUP $3.75 -FDA Decision in September followed by Phase results for another indication . Market cap $79 m - Cash $39 m enough untill mid 2025 potential milestone payment of $10 million upon FDA approval not included . The Drug is already partnered with Viatris (VTRS) . A very cheap FDA play here ...
OCUP $3.75 -FDA Decision in September followed by Phase results for another indication . Market cap $79 m - Cash $39 m enough untill mid 2025 potential milestone payment of $10 million upon FDA approval not included . The Drug is already partnered with Viatris (VTRS) . A very cheap FDA play here ...
DERM $1.70 - Phase 3 data next week if positive this cheap low floater could double fast ...
"Topline data from the DFD-29 Phase 3 clinical studies are expected to be announced in June of 2023."